An overview of peptide categories, selected peer-reviewed studies and long-form conversations with researchers — collected to give context to what we sell in the lab.
Body Protection Compound-157
BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in human gastric juice. In preclinical models it is studied for its interaction with tissue-repair pathways, angiogenesis and gastrointestinal integrity.
Research domains
Thymosin Beta-4 Fragment
TB-500 is a synthetic fragment derived from Thymosin Beta-4. It is studied in experimental systems for its interaction with cell migration, angiogenesis and tissue-repair mechanisms.
Research domains
5 mg BPC-157 + 5 mg TB-500
This blend combines BPC-157 and TB-500 (Thymosin Beta-4 fragment) in a single lyophilised preparation. It is used in experimental systems to study possible synergy between the two recovery-oriented peptides.
Research domains
Copper Tripeptide-1
GHK-Cu is a naturally occurring copper-binding tripeptide studied in research settings for its interaction with tissue remodelling, collagen production and cellular signalling pathways.
Research domains
GHK-Cu + BPC-157 + TB-500
Glow combines GHK-Cu, BPC-157 and TB-500 in a single lyophilised preparation. It is studied in experimental models for the combined interaction of copper tripeptide and recovery-oriented peptides.
Research domains
Growth Hormone Secretagogue (GHS)
Ipamorelin is a synthetic pentapeptide and growth hormone secretagogue (GHS). In research settings it is studied for its selective interaction with the ghrelin receptor (GHS-R1a) and growth hormone release patterns.
Research domains
GHRH analogue (Mod GRF 1-29)
CJC-1295 without DAC (also known as Mod GRF 1-29) is a tetrasubstituted GHRH(1-29) analogue. In preclinical research it is studied for its interaction with the GHRH receptor and pulsatile GH response.
Research domains
Long R3 Insulin-like Growth Factor-1
IGF-1 LR3 is an 83-amino-acid analogue of human Insulin-like Growth Factor-1 with an extended N-terminus and Arg³ substitution. In preclinical setups it is studied for extended half-life and reduced binding to IGFBPs.
Research domains
GHRH analogue
Tesamorelin is a synthetic GHRH analogue (hGHRH(1-44)). In preclinical research it is studied for its interaction with the GHRH receptor and response in visceral-fat-tissue models.
Research domains
Nicotinamide Adenine Dinucleotide
NAD+ (Nicotinamide Adenine Dinucleotide) is a co-enzyme central to cellular energy metabolism. In research settings it is studied for its role in mitochondrial function, DNA repair and sirtuin signalling.
Research domains
Heptapeptide analogue of ACTH(4-10)
Semax is a synthetic heptapeptide derived from a fragment of adrenocorticotropic hormone (ACTH 4-10). In preclinical research it is studied for interaction with BDNF expression and neurotrophic signalling in CNS models.
Research domains
Delta Sleep Inducing Peptide
DSIP (Delta Sleep Inducing Peptide) is a 9-amino-acid peptide originally isolated from rabbit brain during delta sleep. In preclinical research it is studied for interaction with sleep architecture and stress-response models.
Research domains
Bremelanotide — Melanocortin receptor agonist
PT-141 (bremelanotide) is a synthetic heptapeptide and agonist of the melanocortin-3 and -4 receptors. In preclinical research it is studied for interaction with CNS pathways around sexual response and appetite regulation.
Research domains
Synthetic α-MSH analogue
Melanotan-2 is a cyclic heptapeptide and non-selective agonist of melanocortin receptors (MC1-5R). In preclinical research it is studied for interaction with pigmentation pathways and MC4R-mediated signalling.
Research domains
Triple GIP / GLP-1 / Glucagon Receptor Agonist
Retatrutide (LY3437943) is a multi-receptor agonist peptide. In preclinical research it is studied for its simultaneous interaction with GIP, GLP-1 and glucagon receptors in metabolic models.
Research domains
External links to peer-reviewed journals and review papers. Peptica does not host or own this content.
Nature Reviews Endocrinology
Overview of glucagon-like peptide-1 receptor agonists, their mechanism of action and the downstream metabolic effects observed in preclinical models.
Frontiers in Pharmacology
Systematic review of preclinical data on BPC-157 in models of tissue repair, tendon healing and gastrointestinal protection.
Endocrine Reviews
Review of GHRH analogues and ghrelin receptor agonists, including pulsatile GH release kinetics and receptor selectivity.
Journal of Investigative Dermatology
Background on the melanocortin system and α-MSH analogues used as research tools in studies on pigmentation and appetite regulation.
Carefully selected long-form episodes with scientists and clinicians. Videos embedded via YouTube.
HUBERMAN LAB
An in-depth conversation on mechanisms, study design and the gap between preclinical and clinical evidence for popular research peptides.
PETER ATTIA, MD
A deep dive into incretin biology, semaglutide/tirzepatide mechanisms, and how researchers interpret weight and cardiovascular endpoints.
ANDREW HUBERMAN, PHD
An in-depth episode on the major peptide categories — BPC-157, tissue repair, GH secretagogues — and how researchers weigh risk and evidence.
DR. ABOOD BAKRI & ANDREW HUBERMAN
A conversation with an internist about FDA-approved GLP-1 agonists, BPC-157, GH secretagogues and the difference between clinical evidence and the grey market.
